Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 8/20 | 0.54 |
| ▸ | CA2 | P00918 | 8/20 | 0.54 |
| ▸ | CA9 | Q16790 | 8/20 | 0.54 |
| ▸ | CA12 | O43570 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974848 | 0.86 | CA12 (0.66) | LMNACA1CA2CA9CA12 | |
| SCHEMBL16392904 | 0.85 | LMNA (0.51) | LMNAKMT2ACA1CA2CA9 | |
| SCHEMBL13866730 | 0.84 | CA12 (0.68) | CA1CA2CA9CA12CYP2D6 | |
| Hydrochloric Acid SCHEMBL5741360 | 0.84 | LMNA (0.50) | LMNAKMT2ACA1CA2CA9 | |
| SCHEMBL21133688 | 0.84 | LMNA (0.50) | LMNAKMT2ACA1CA2CA9 | |
| SCHEMBL25480951 | 0.83 | LMNA (0.57) | LMNAKMT2ACA1CA2CA9 | |
| SCHEMBL21366081 | 0.83 | LMNA (0.57) | LMNAKMT2ACA1CA2CA9 | |
| SCHEMBL24378476 | 0.83 | LMNA (0.57) | LMNAKMT2ACA1CA2CA9 | |
| SCHEMBL20516514 | 0.83 | LMNA (0.69) | LMNAKMT2ACA1CA2CA9 | |
| SCHEMBL20643514 | 0.83 | LMNA (0.57) | LMNAKMT2ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | RTCB, IGF2BP2, SNRPE | LMNA 382/4885KMT2A 2695/4885CA1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.